Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393055 | 0.81 | HSP90AB1 (0.54) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3391542 | 0.78 | HDAC6 (0.57) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3269795 | 0.77 | ADORA2A (0.64) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3396010 | 0.75 | HDAC6 (0.48) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL6272417 | 0.75 | ALDH1A1 (0.66) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3392706 | 0.74 | HSP90AB1 (0.72) | HSP90AB1HSP90AA1 | |
| SCHEMBL3390714 | 0.74 | HDAC6 (0.54) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3393881 | 0.74 | HDAC1 (0.49) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL23416524 | 0.73 | ADORA2A (0.63) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3392317 | 0.72 | HSP90AB1 (0.58) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HDAC6 541/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HDAC6 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.